Influence of Sutent on Tumor Vascularization and Necrosis in Patients With Renal Cell Carcinoma

A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma

NCT00480935 ·Status: TERMINATED ·Phase: PHASE2

An Exploratory Correlative Study of Biomarkers in Patients With Metastatic Renal Cell Carcinoma Who Have Progressed After Sunitinib Therapy

NCT00538772 ·Status: WITHDRAWN

Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC)

NCT01069770 ·Status: UNKNOWN ·Phase: PHASE2

Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer

NCT00465179 ·Status: COMPLETED ·Phase: PHASE2

Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma

NCT01070186 ·Status: WITHDRAWN ·Phase: PHASE2

Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain

NCT00814021 ·Status: COMPLETED ·Phase: PHASE2

Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)

NCT00715442 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Study Of SU011248 (Sunitinib) Given In A Continuous Daily Regimen In Patients With Advanced Renal Cell Cancer

NCT00137423 ·Status: COMPLETED ·Phase: PHASE2

The Vascular and Metabolic Effects of Sunitinib in Patients With Metastatic Renal Cell Carcinoma

NCT01227213 ·Status: COMPLETED

Evaluation of Cognitive Function of Patients With Sunitinib or Sorafenib

NCT01246843 ·Status: COMPLETED

Sunitinib Before or After Surgery in Treating Patients With Metastatic Kidney Cancer

NCT00626509 ·Status: UNKNOWN ·Phase: PHASE2

Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule

NCT01499121 ·Status: COMPLETED ·Phase: PHASE2

Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma

NCT00130897 ·Status: APPROVED_FOR_MARKETING

Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC Patients

NCT01934452 ·Status: COMPLETED

A Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Received a Medicine Called Sunitinib Responded to This Medicine.

NCT05745142 ·Status: COMPLETED

Study of Sunitinib Administered as 4/2 vs. 2/1 Schedule in Advanced Renal Cell Carcinoma (RCC)

NCT00570882 ·Status: COMPLETED ·Phase: PHASE2

Stereotactic Radiotherapy for Metastatic Kidney Cancer Being Treated With Sunitinib

NCT02019576 ·Status: COMPLETED ·Phase: PHASE2

Evaluation Of The Impact Of A Call Center In Management Of Metastatic And/Or Advanced Renal Cell Carcinoma Patients Treated With Sunitinib (Sutent) In First Line

NCT02187042 ·Status: COMPLETED

Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma

NCT00556049 ·Status: COMPLETED ·Phase: PHASE2

Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response

NCT00694096 ·Status: COMPLETED ·Phase: PHASE1

Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer

NCT00717587 ·Status: UNKNOWN ·Phase: PHASE2

Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®

NCT00684645 ·Status: COMPLETED

Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma

NCT02071641 ·Status: TERMINATED ·Phase: PHASE2

Trial Of Sunitinib In Advanced Non-Clear Cell Type Renal Cell Carcinoma

NCT01219751 ·Status: UNKNOWN ·Phase: PHASE2

Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma

NCT00930345 ·Status: TERMINATED ·Phase: PHASE4